Long-term outcome of a low-dose intravesical bacillus Calmette-Guerin therapy for carcinoma Iin situ of the bladder: Results after six successive instillations of 40 mg BCG

Japanese Journal of Clinical Oncology

Volumn 35, Issue 7, 2005, Pages 395-399

  Mugiya, Soichi ^a   Ozono, Seiichiro ^a   Nagata, Masao ^a   Takayama, Tatsuya ^a   Ito, Toshiki ^b   Maruyama, Satoshi ^b   Hadano, Shinsuke ^b   Nagae, Hiroshi ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

Author keywords

Adverse effect; BCG; CIS; Low dose; Tokyo 172 strain

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER IRRITATION; CARCINOMA IN SITU; CYSTECTOMY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INSTILLATION; DRUG SAFETY; DYSURIA; FEMALE; FEVER; HEMATURIA; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MALE; PYURIA; TREATMENT OUTCOME; URINARY FREQUENCY; BLADDER TUMOR; DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; RETROSPECTIVE STUDY;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 24944459948     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi111     Document Type: Article

References (22)

1. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumor. J Urol 1976;116:180-3.
2. Ovesen H, Poulsen A, Steven K. Intravesical bacillus Calmette-Guerin with the Danish strain for treatment of carcinoma in situ of the bladder. Br J Urol 1993;72:744-8.
3. Lamm DL. BCG immunotherapy for transitional cell carcinoma in situ of the bladder. Oncology 1995;9:947-65.
4. Akaza H, Hinostu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 1995;75:552-9.
5. Akaza H, Kameyama S, Koiso K, Kakizoe T, Kojima H, Umeda T, et al. Analyses of the effects of intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy for superficial bladder cancer. Nippon Hinyokika Gakkai Zasshi 1989;80:167-74 (in Japanese).
6. Kudo S, Tsushima N, Sawada Y, Saito F, Motomura F, Takashima T, et al. Serious complications of intravesical bacillus Calmette-Guerin therapy in patients with bladder cancer. Nippon Hinyokika Gakkai Zasshi 1991; 82:1594-602 (in Japanese).
7. Takashi M, Wakai K, Ohno Y, Murase T, Miyake K. Evaluation of a low-dose intravesical bacillus Calmette Guerin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol 1995;27:723-33.
8. Irie A, Uchida T, Yamashita H, Matsumoto K, Satoh T, Koh H, et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guerin for superficial bladder cancer recurrence. Int J Urol 2003;10:183-9.
9. Kurth KH, Schellhammer PF, Okajima E, Akdas A, Jakse G, Herr HW, et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int J Urol 1995;2:8-22.
10. Japanese Urological Association and Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Bladder Cancer, 3rd edn. Tokyo: Kanehara Shuppann 2001 (in Japanese).
11. Lamm DL, Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
12. Akaza H, Kameyama S, Kakizoe T, Kojima H, Koiso K, Aso Y, et al. Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Nippon Hinyokika Gakkai Zasshi 1992;83:183-9 (in Japanese).
13. Ikeda N, Honda I, Yano I, Koyama A, Toida I. Bacillus Camette-Guerin Tokyo 172 substrain for superficial bladder carcinoma: Characterization and antitumor effect. J Urol 2005;173:1507-12.
14. Ozono S, Takahashi K, Tanaka N, Momose H, Hirao Y, Okajima E, et al. Intravesical bacillus Calmette-Guerin (BCG) therapy for carcinoma in situ of the urinary bladder - outcomes of a randomized study. Ann Soc BCG BRM Immunother 1996;20:95-100 (in Japanese).
15. Okaneya T, Ikado S, Murata Y, Niwakawa M, Mizusawa H, Yamaguchi K, et al. Intravesical bacillus Calmette-Guerin instillation for in situ and superficial bladder carcinoma: Results of ten successive instillations of 40 milligrams. Jpn J Clin Urol 1991;45:129-32 (in Japanese).
16. Okaneya T, Komiyama M, Niwakawa M, Murata Y, Nishizawa O. Long-term outcome of intravesical bacillus Calmette-Guerin instillation for bladder carcinoma: Results of 8 to 14 successive instillation of 40 mg BCG for treatment or prophylaxis. Ann Soc BCG BRM Immunother 1999;23:71-5 (in Japanese).
17. Takashi M, Katsuno S, Yuba H, Ohshima S, Wakai K, Ohno Y. Possible factors affecting response to intravesical bacillus Calmette-Guerin (Tokyo 172 Strain) therapy for carcinoma in situ of the bladder. Int Urol Nephrol 1998;30:713-22.
18. Harada Y, Seguchi T, Nonomura N, Kojima Y, Miki T, Okuyama A. Clinical study of carcinoma in situ of the urinary bladder. Nippon Hinyokika Gakkai Zasshi 1998;89:693-7 (in Japanese).
19. Ozono S, Kagebayashi Y, Yamamoto H, Mibu H, Horikawa N, Hirayama A, et al. Methods to evaluate response to BCG instillation therapy for CIS. Ann Soc BCG BRM Immunother 2000;24:55-9 (in Japanese).
20. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: Long-term results. J Urol 2000;163:68-72.
21. Koga H, Kuroda M, Kudo S, Yamaguchi A, Usami M, Suzuki T, et al. Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. Int J Urol 2005;12:145-51.
22. Lamm DL. BCG immunotherapy for transitional cell carcinoma in situ of the bladder. Oncology 1995;9:947-65.